Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bortezomib + BX-912|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BX-912||PDPK1 Inhibitor 10||BX-912 is a small molecule inhibitor of PDPK1, which may result in cell growth inhibition and apoptotic activity (PMID: 15772071, PMID: 29287939).|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|